Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Pembrolizumab versus paclitaxel bij maagkanker
jul 2018 | Immuuntherapie, Maag-darm-leveroncologie